Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
Top Cited Papers
Open Access
- 20 April 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 63 (2), 234-241
- https://doi.org/10.1093/cid/ciw243
Abstract
Ceftolozane/tazobactam and ceftazidime/avibactam are 2 novel β-lactam/β-lactamase combination antibiotics. The antimicrobial spectrum of activity of these antibiotics includes multidrug-resistant (MDR) gram-negative bacteria (GNB), including Pseudomonas aeruginosa. Ceftazidime/avibactam is also active against carbapenem-resistant Enterobacteriaceae that produce Klebsiella pneumoniae carbapenemases. However, avibactam does not inactivate metallo-β-lactamases such as New Delhi metallo-β-lactamases. Both ceftolozane/tazobactam and ceftazidime/avibactam are only available as intravenous formulations and are dosed 3 times daily in patients with normal renal function. Clinical trials showed noninferiority to comparators of both agents when used in the treatment of complicated urinary tract infections and complicated intra-abdominal infections (when used with metronidazole). Results from pneumonia studies have not yet been reported. In summary, ceftolozane/tazobactam and ceftazidime/avibactam are 2 new second-generation cephalosporin/β-lactamase inhibitor combinations. After appropriate trials are conducted, they may prove useful in the treatment of MDR GNB infections. Antimicrobial stewardship will be essential to preserve the activity of these agents.Keywords
Funding Information
- National Institutes of Health
- NIH
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH (UM1AI104681, 1R21AI114508, ))
- Veterans Affairs Merit Review (1I01BX001974, ))
- NIAID
- NIH (R01AI063517, R01AI100560)
- NIH (UM1AI104681)
- NIH (R01AI072219)
- NIH
This publication has 52 references indexed in Scilit:
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized studyCurrent Medical Research and Opinion, 2012
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences of the United States of America, 2012
- Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazoleInternational Journal of Antimicrobial Agents, 2012
- Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending DosesAntimicrobial Agents and Chemotherapy, 2012
- In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2012
- In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)Antimicrobial Agents and Chemotherapy, 2011
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemasesJournal of Antimicrobial Chemotherapy, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerationsClinical Microbiology & Infection, 2005
- CeftazidimeDrugs, 1995